Methicillin Resistant Staphylococcus aureus Monoclonal Antibody Prophylactic and Therapeutic
Monoclonal antibody for passive immunotherapy treatment of Methicillin Resistant Staphylococcus aureus (MRSA) infections that occur following joint replacement surgeries.
Acinetobacter baumanii
Passive immunotherapy for treatment of Acinetobacter baumanii, a rapidly increasing cause of severe, hospital-acquired infections.
2011 BIO International Convention in Washington D.C.
Read More
Codevax, Inc. is a vaccine company focused on developing immunizations and treatments for hospital acquired infections with emphasis on MRSA infections and osteomyelitis associated with bone and joint replacement surgery. Codevax has a parallel research program targeting another challenging hospital-acquired infection Acinetobacter baumannii.